Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
University of Calgary
Headquarters: Calgary, AB, Canada
Website: http://www.ucalgary.ca
Year Founded: 1966
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jan 1, 2021
Targets & Mechanisms
A snapshot of target innovation in 2020
An analysis of BioCentury’s Distillery captures trends from preclinical publications in 2020
BioCentury | Oct 28, 2020
Distillery Therapeutics
Inhibiting IL-33-driven inflammation to treat brain cancer
DISEASE CATEGORY: Cancer
INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the
INDICATION: Brain cancer Targeting nuclear accumulation of IL-33 could treat glioblastoma multiforme by reducing recruitment of pro-tumorigenic innate immune cells to the
BioCentury | Apr 15, 2019
Distillery Therapeutics
MedImmune's bispecific mAb for Pseudomonas-related ocular keratitis
BioCentury | Jul 19, 2018
Translation in Brief
Inflammatory images
How inflammasome activation mediates contrast agent-induced acute kidney injury
Items per page:
1 - 10 of 57